SCN4A and Myotonia: Current treatment for myotonia primarily focuses on the symptomatic relief of enhanced muscle tone with action potential-reducing agents such as Mexiletine, which exerts use-dependent block of surface voltage-gated Na+ channels (NaV1.4) in skeletal muscles55, 56, 57.